CompletedPhase 3

Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion

Japan80 participantsStarted 1999-08

Plain-language summary

The purpose of this study is to evaluate the efficacy of pericardial instillation of bleomycin as a sclerosing agent after pericardial drainage for lung cancer-associated malignant pericardial effusion.

Who can participate

Age range

75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Pathologically documented lung cancer * Clinically stable condition after pericardial drainage for malignant pericardial effusion (not necessary that it be documented by cytology) * Expected to live 6 weeks or longer * Sufficient organ function * Signed informed consent Exclusion Criteria: * Myocardial infarction or unstable angina within 3 months * Constrictive pericarditis * Active pneumonitis * Severe infection or disseminated intravascular coagulation (DIC) * Other severe co-morbidity which could not be relieved with pericardial drainage * Chemotherapy-naive small cell lung cancer

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Survival without pericardial effusion at 2 months

Trial details

NCT IDNCT00132613

SponsorJapan Clinical Oncology Group

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2006-11

View on ClinicalTrials.gov More Malignant Pericardial Effusion trials

Who can participate

Age range

75 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.